Double-Dye MRI could sharpen liver cancer detection
NCT ID NCT02156739
First seen Jan 05, 2026 · Last updated Jun 19, 2026 · Updated 29 times
Summary
This study tests whether using two contrast dyes during MRI can better tell apart benign and malignant liver lesions. About 100 patients with known or suspected liver growths will receive both gadoxetate disodium and gadobutrol before imaging. The goal is to see if the combination improves accuracy compared to using one dye alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Gadoxetate disodium and gadobutrol (contrast dyes given by IV)
What this could lead to
If successful, this could lead to more accurate MRI scans for liver lesions, helping doctors tell harmless from cancerous growths without invasive biopsies.
What could go wrong
This is a small, early-stage imaging study, not a treatment trial. The results may not apply to all patients or scanners, and the contrast dyes carry a small risk of allergic reaction or kidney injury.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.